| Title |
Interferon beta for secondary progressive multiple sclerosis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2012
|
| DOI | 10.1002/14651858.cd005181.pub3 |
| Pubmed ID | |
| Authors |
Loredana La Mantia, Laura Vacchi, Carlo Di Pietrantonj, George Ebers, Marco Rovaris, Sten Fredrikson, Graziella Filippini |
| Abstract |
Therapy with either recombinant beta-1a or beta-1b interferons (IFNs) is worldwide approved for Relapsing Remitting Multiple Sclerosis (RRMS). A major unanswered question is whether this treatment is able to safely reverse or retard the progressive phase of the disease. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 154 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| Turkey | 1 | <1% |
| France | 1 | <1% |
| Unknown | 150 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 17% |
| Researcher | 22 | 14% |
| Student > Master | 22 | 14% |
| Other | 11 | 7% |
| Student > Bachelor | 10 | 6% |
| Other | 25 | 16% |
| Unknown | 38 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 58 | 38% |
| Psychology | 10 | 6% |
| Agricultural and Biological Sciences | 6 | 4% |
| Nursing and Health Professions | 6 | 4% |
| Neuroscience | 6 | 4% |
| Other | 23 | 15% |
| Unknown | 45 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2022.
All research outputs
#1,148,707
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#2,355
of 11,499 outputs
Outputs of similar age
#7,178
of 251,889 outputs
Outputs of similar age from Cochrane database of systematic reviews
#26
of 231 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 231 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.